You are here: Home1 / Technology overview
/wp-content/uploads/2024/10/CompanyName-300x300.png
0
0
gatekeeper
/wp-content/uploads/2024/10/CompanyName-300x300.png
gatekeeper2025-02-13 14:01:392025-02-17 08:33:47Using targeted mass spectrometry to characterize the mechanism of action for a novel T cell-priming vaccine delivery system
/wp-content/uploads/2024/10/CompanyName-300x300.png
0
0
gatekeeper
/wp-content/uploads/2024/10/CompanyName-300x300.png
gatekeeper2025-02-13 13:46:152025-02-13 14:09:54New approach: MHC class I peptide libraries for the treatment of viral and bacterial infectious diseases by innovative multi-epitope T cell adaptive vaccines
/wp-content/uploads/2024/10/CompanyName-300x300.png
0
0
gatekeeper
/wp-content/uploads/2024/10/CompanyName-300x300.png
gatekeeper2025-02-13 13:45:282025-03-19 10:02:38Rapid Emergex Antigen Deployment Initiative (READI): a synthetic T cell vaccine technology platform pairing a gold nanoparticle delivery system with select targets from a ligandome of prescreened pathogen derived, naturally processed & presented MHC-I peptides to provide rapid response solutions to combat and broadly protect against biothreat pathogens
/wp-content/uploads/2024/10/CompanyName-300x300.png
0
0
gatekeeper
/wp-content/uploads/2024/10/CompanyName-300x300.png
gatekeeper2025-02-13 13:44:412025-03-19 10:01:34Characterization of a T cell adaptive vaccine platform to prime a broad and durable immunogenic response against Dengue virus infection
/wp-content/uploads/2024/10/CompanyName-300x300.png
0
0
gatekeeper
/wp-content/uploads/2024/10/CompanyName-300x300.png
gatekeeper2025-02-13 13:41:032025-02-18 09:48:29Emergex’s Next Generation Vaccines: Naturally processed & presented MHC class I ligandome libraries for the development of T cell priming immune set-point vaccines against infectious pathogens
Scroll to top
